DENSE-AIR
Dense Air & Dublin City Council win the 2019 Small Cell Forum Award for Social Impact – ‘Promoting Small Cells for Social/Economic/Environmental Development’. It follows successful completion of the first phase of a ground breaking 5G research and development network in Dublin’s Docklands delivered as part of the Dublin City Council (DCC) ‘Smart Docklands’ initiative.
This strategic partnership between Dense Air and DCC announced in January 2018 was intended to provide a framework for the large-scale deployment of a “pervasive” 5G connectivity solution across Dublin, and also intended to develop a blue print for future deployments globally. The initial findings have demonstrated that Neutral Host Small Cells can provide unrivalled benefits to cities and mobile operators.
Working with City council departments, national agencies, building owners and the Science Foundation Ireland CONNECT Research Centre for future networks based in TCD, Dense Air have focused on understanding how best to deploy small cells on city owned street assets build neutral-host infrastructure that can be used simultaneously, by multiple mobile network providers and private networks to simplify the small cell installation process. Having an efficient, affordable, scalable and repeatable processes, are key factors in deploying 5G small cells networks, where densification and improved indoor performance will require access to city street assets including lamp posts and traffic lights.
The judging panel stated that: “There are many interesting smart city projects involving small cells but the collaboration between Dense Air and Dublin City Council stands out for the variety of services supported, and well-quantified benefits to citizens, businesses and visitors The judges were also impressed by the neutral host model, which they believe will be very significant in lowering barriers to deployment of large networks.”
Jamie Cudden, Smart City Program Manager said:“Dublin City Council is delighted to be recognised by the Small Cell Forum for our collaboration with Dense Air. The delivery of this project was only possible through collaboration with the CONNECT research centre for future networks, local building owners and the engagement of our wider Smart Docklands partner network.
“Pervasive connectivity offers cities a clear competitive advantage and we are now ideally placed to provide a perfect live 5G test environment for companies to work with us to trial services that can help us solve different challenges. Furthermore Dublin is now providing other cities globally a template for how they can realise the future 5G opportunity.”
Paul Senior , CEO of Dense Air said “We are absolutely thrilled to have received two awards at the 2019 Small Cell Forum World Summit in London. These awards recognise Dense Air’s unique neutral host business model based on densification using small cells, and deployment and engagement we have with cities, namely Dublin City Council.”
Building on the success of this project, Dublin City Council will host the prestigious Harvard TECH Innovators Forum in partnership with Dense Air from 7-9th October 2019; Bringing together city technology leaders from across the world to share emerging best practice for 5G deployments and showcasing the Dublin Docklands 5G Pervasive Network.
Dr. David Ricketts, Innovation Fellow in the Technology in Entrepreneurship Center at Harvard (TECH) comments that, ”We are delighted to bring together cities in Dublin to share best practice experiences on how they can manage disruptive technologies in a way that will allow us to build better communities for everyone. This unique gathering will bring the top global city technology leaders together to better understand how cities can best leverage and lead on the 5G opportunity.”
https://theinnovatorsforum.org/
Dense Air is headquartered in London, UK and has offices in the target launch markets of Ireland, Belgium, Portugal, Australia & New Zealand. Dense Air provides a unique “carrier of carriers” wholesale neutral host small cell services to deliver cost-effective densification to existing mobile carriers or service providers. Dense Air is conducting extensive trials and proof-of-concepts in 2019 and will offer commercial services in 2020. Dense Air provides small cell services in Ireland based on licensed 3.4-3.8GHz radio spectrum awarded by Ireland regulator in 2017.
Dublin City Council (DCC) is leading a series of innovative partnerships with world-leading technology companies through its Smart Dublin initiative. The Smart Docklands district was set up in February 2018 to deliver and fast-track smart city projects and deployments and understand the different types of connectivity and networks that would enable future cities. This was established in partnership with CONNECT, a national research centre for connectivity and future networks. Smart Docklands was a first of its kind in Ireland, where the municipality and academia have created a dedicated Project Management Office (PMO) to play an independent role amongst multiple stakeholders, from global technology companies to local residents’ groups, from academic institutions to international property developers, innovative start-ups and SMEs to fast track emerging smart city opportunities. http://smartdocklands.ie/
View source version on businesswire.com: https://www.businesswire.com/news/home/20190605005708/en/
Contact:
Dense Air Paul Coffey Tel: 01895 467100 www.denseair.net
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom